Regulatory FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept) Big Molecule WatchOn April 2, 2026, Regeneron Pharmaceuticals announced that the U.S.RegulatoryOphthalmologyRead full story pharminent April 15, 2026 Big Molecule Watch On April 2, 2026, Regeneron Pharmaceuticals announced that the U.S. RegulatoryOphthalmologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly to acquire CrossBridge Bio for up to $300mNext: Travere wins long-awaited approval for kidney disease drug Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
